Artiva Biotherapeutics Inc (ARTV)
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company listed on Nasdaq under the ticker ARTV. The company is focused on developing natural killer, or NK, cell-based therapies for autoimmune diseases and cancer. Its lead candidate, AlloNK, is an off-the-shelf NK cell therapy being studied for conditions including rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, pemphigus vulgaris, ANCA-associated vasculitis subtypes, and B-cell non-Hodgkin lymphoma. Artiva is also advancing AB-201, an allogeneic CAR-NK program directed at HER2 for solid tumors such as breast, gastric, esophageal, and bladder cancers, as well as AB-205, an allogeneic CAR-NK candidate targeting CD5 for hematological malignancies. Founded in 2019, the company is headquartered in San Diego, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ARTV
|
$7.99
|
-18.4% Downside
|
Overvalued
|
$35.80
|
265.7% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 27, 2026
|
-5.4x
|
5.3x
|
—
|
444.6 M
|
389.9 M
|
2.3%
|
40.8%
|
8.1
|
—
|
92.1%
|
